Amrut Drug Research Lab Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 05-01-2025
- Paid Up Capital ₹ 0.98 M
as on 05-01-2025
- Company Age 36 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -20.97%
(FY 2022)
- Profit -10.41%
(FY 2022)
- Ebitda -130.19%
(FY 2022)
- Net Worth -9.48%
(FY 2022)
- Total Assets 10.10%
(FY 2022)
About Amrut Drug Research Lab
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.98 M, as per Ministry of Corporate Affairs (MCA) records.
Pramod Mitna and Bharat Mitna serve as directors at the Company.
- CIN/LLPIN
U24235MH1988PTC048601
- Company No.
048601
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 1988
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Amrut Drug Research Lab Pvt Ltd offer?
Amrut Drug Research Lab Pvt Ltd offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Pain Killers, Erectile Dysfunction Medicine, Erectile Dysfunction Spray, Antifungal Cream, Ointment & Powder, Pain Relief Spray, Ear Drops, Face Cream, Anti Aging Cream, Clobetasol Propionate Cream.
Who are the key members and board of directors at Amrut Drug Research Lab?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Mitna  | Director | 22-Aug-2014 | Current |
| Bharat Mitna | Director | 27-Mar-2019 | Current |
Financial Performance of Amrut Drug Research Lab.
Amrut Drug Research Lab Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 20.97% decrease. The company also saw a substantial fall in profitability, with a 10.41% decrease in profit. The company's net worth dipped by a decrease of 9.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amrut Drug Research Lab?
In 2022, Amrut Drug Research Lab had a public holding of 64.95%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Amrut Drug Research Lab?
Unlock and access historical data on people associated with Amrut Drug Research Lab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amrut Drug Research Lab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amrut Drug Research Lab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
